Analysis of the Expression of the TRBC1 in T lymphocyte tumors
- PDF / 1,651,475 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 95 Downloads / 183 Views
ORIGINAL ARTICLE
Analysis of the Expression of the TRBC1 in T lymphocyte tumors Man Chen1 • Aixian Wang1 • Shuqiang Liu2 • Xueying Wu1 • Meiwei Gong1 Junyi Zhen1 • Minjing Fu3 • Hui Wang1
•
Received: 19 February 2020 / Accepted: 16 September 2020 Ó Indian Society of Hematology and Blood Transfusion 2020
Abstract T cell therapy represents a new class of immunotherapies garnering considerable attention. T cell receptor beta chain constant region 1 (TRBC1) is partially expressed in subsets of normal T cells. However, the immunotherapy of T lymphocyte tumors is rarely validated in clinical trials. Here, we aim to explore whether TRBC1 is a promising target for the immunotherapy of T lymphocyte tumors. This study examined TRBC1 expression in 25 healthy bone marrow samples, 39 patients with T-lineage acute lymphocytic leukemia (T-ALL), 4 patients with mature T cell neoplasms, and 5 patients suspected with mature T cell neoplasms with evidence of T cell neoplasia. Moreover, the expression of TRBC1 was evaluated by flow cytometry and through PCR detection of TCR gene rearrangements. The expression of monophasic TRBC1 was identified in all 25 normal bone marrows (23.83% ± 2.74% positive rate). The expression of TRBC1 was positive in 5 patients (12.8%) among the 39 TALL patients. TRBC1 was partially expressed in 1 patient (25%) with T cell non-Hodgkin’s lymphoma (T-NHL) and in 1 patient (20%) suspected to have T-NHL. Healthy donors showed a pattern of partial expression and patients with T-lymphocyte tumors showed a polytypic TRBC1
& Hui Wang [email protected] 1
Department of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, No.2 Siplan Road, Yanjiao Development Zone, Langfang 065201, Hebei, China
2
Tianjin Mycure Medical Technology Co., Ltd., Wuqing 301700, Tianjin, China
3
Department of Pathology and Laboratory Medicine, Beijing Lu Dao-Pei Hospital, Beijing 100176, China
expression pattern. Thus, TRBC1 may be a diagnostic and therapeutic marker for T lymphocyte tumors. Keywords T lineage acute lymphocytic leukemia T cell receptor b chain constant region 1 Flow cytometry T cell receptor rearrangement
Introduction T-lineage acute lymphoblastic leukemia (T-ALL) comprises up to 25% of all acute lymphoblastic leukemia (ALL) cases [1, 2], including early cortical, late cortical, and mature T cell stages. In 2016, the World Health Organization updated the classification of lymphoid neoplasms to include 27 mature T cell neoplasms [3]. Peripheral T cell lymphoma-not otherwise specified (PTCL-NOS; 26%) is the most common subgroup of T cell lymphoma, followed by angioimmunoblastic lymphoma (18%). Natural killer/T cell lymphoma (NKTCL) and adult T cell leukemia/lymphoma (ATL) represent 12% and 10% of cases, respectively [4]. PTCL is a heterogeneous group of tumors [5], accounting for 15%-20% of aggressive nonHodgkin’s lymphomas (NHL) in Western countries [6–8], and is more common in middle-aged/elderly patients with stage III to IV disease, with nodal and/or extranodal locations [9–11], who die rapi
Data Loading...
